Radioimmunoguided surgery using radiolabeled NR-LU-10 Fab was evaluated as a method of intraoperative breast cancer detection.
Methods
Breast cancer patients were injected intravenously with 125I (74 MBq) labeled NR-LU-10 Fab (5 mg) and then underwent tumor excision 2, 4 or 7 days later, during which time the gamma detector probe was used to evaluate the primary tumor for evidence of radioactive uptake.
Results
Intraoperative probing revealed tumor localization in 7 of 10 patients (70%). Gamma probe counts of the excised tumor were elevated in all patients, although high counts in surrounding nonmalignant tissue obscured the ability to detect the tumor in vivo in 3 patients. One patient with bilateral breast cancer was found to have a separate focus of occult tumor in each breast using the gamma detector probe.
Conclusions
Radiolabeled NR-LU-10 Fab possesses favorable pharmokinetics and tumor-binding ability as a targeting agent. However, binding to nonmalignant tissue limits its role in the intraoperative evaluation of tumor margins in breast cancer patients. Its role in other malignancies should be explored.
Blichert-ToftM., RoseC., AndersenJ., OvergaardM., AxelssonC.K., AnersenK.W., MouridsenH.T.: Danish randomized trial comparing breast conservation therapy with mastectomy; six years of life-table analysis.J Natl Cancer Inst Monogr,11: 19–25, 1992.
2.
FisherB., RedmondC., PoissonR., MargoleseR., WolmarkN., WickerhamL., FisherE., DeutschM., CaplanR., PilchY.: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.N Engl J Med,320: 822–828, 1989.
3.
LichterA., LippmanM., DanforthD.N.Jr., diAngeloT., SteinbergS.M., deMossE., MacDonaldH.D., ReichertC.M., MerinoM., SwainS.M.: Mastectomy versus breast conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute.J Clin Oncol,10: 976–983, 1992.
4.
Van DongenJ., BartelinkH., FentimenI.S., LerutT., MignoletF., OlthuisG., Van der SchuerenE., SylvesterR., WinterJ., VanZijlK.: Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial.J Natl Cancer Inst Monogr,11: 15–18, 1992.
5.
VeronesiU., BanfiA., SalvadoriB., LuiniA., SaccozziR., Zu-caliR., MarubiniE., DelVecchioM., BoracchiP., MarchiniS.: Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized clinical trial.Eur J Cancer,26: 668–670, 1990.
6.
AnscherM.S., JonesP., ProsnitzL.R., BlackstockW., HebertM., ReddickR., TuckerA., DodgeR., LeightG.Jr., IglehartJ.D.: Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy.Ann Surg,218: 22–28, 1993.
7.
SpivackB., KhannaM.M., TafraL., JuillardG., GiulianoA.E.: Margin status and local recurrence after breast-conserving therapy.Arch Surg,129: 952–957, 1994.
8.
OlivettoI.A., RoseM.A., OsteenR.T., LoveS., CadyB., SilverB., RechtA., HarrisJ.R.: Late cosmetic outcome after conservative surgery and radiotherapy: analysis of causes of cosmetic failure.Int J Radiat Oncol Phys,17: 747–753, 1989.
9.
Van LimbergenE., RijndersA., Van der SchuerenE., LerutT., ChristiaensR.: Cosmetic evaluation of breast conserving treatment for mammary cancer: a quantitative analysis of the influence of radiation dose, fractionation, schedules, and surgical treatment techniques on cosmetic results.Radiother Oncol,116: 253–267, 1989.
10.
WazerD., DiPetrilloT., Schmidt-UllrichR., WeldL., SmithT.J., MarchantD.J., RobertN.J.: Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma.J Clin Oncol,10: 356–363, 1992.
11.
ArnoldM.W., SchneebaumS., BerensA., PettyL., MojzisikC., HinkleG., MartinE.W.Jr.: Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody.Ann Surg,216: 627–632, 1992.
12.
MartinD.T., AitkenD.R., ThurstonM.O., HaagensinD., HinkleG., OlsenJ., HouchensD., OvejeraA., CareyL.C., MartinE.W.Jr.: Successful experimental use of a self-contained gamma detecting device.Curr Surg,41: 193–197, 1984.
13.
SardiA., WorkmanM., MojzisikC., HinkleG., NierodaC., MartinE.W.Jr.: Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system).Arch Surg,124: 55–59. 1989.
14.
BadellinoF., BertoglioS., MarianiG., MeszarosP., CanaveseG., PercivaleP.: Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancer.Semin Surg Oncol,15: 245–248, 1998.
15.
NierodaC.A., MojzisikC., SardiA., FarrarW.B., HinkleG., Sid-diqiM.A., FerraraP.J., JamesA., SchlomJ., ThurstonM.O.: Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3.Surg Gynecol Obstet,169: 35–40, 1989.
16.
PercivaleP., BertoglioS., MeszarosP., CanaveseG., CafieroF., GipponiM., CamporaE., GascoM., BadellinoF.: Radioimmunoguided surgery after primary treatment of locally advanced breast cancer.J Clin Oncol,14: 1599–1603, 1996.
17.
OkabeT., KaizuT., FujisawaM., WatanabeJ., KojimaK., YamashitaT., TakakuF.: Monoclonal antibodies to surface antigens of small cell carcinoma of the lung.Cancer Res,44: 5273–5278, 1984.
18.
VarkiN.M., ReisfieldR.A., WalkerL.E.: Antigens associated with human lung adenocarcinoma defined by monoclonal antibodies.Cancer Res,44: 681–687, 1984.
19.
ClarkD.H., MartinezA.A.: Identification of patients who are at high risk for locoregional breast cancer recurrence after conservative surgery and radiotherapy: a review article for surgeons, pathologists, and radiation and medical oncologists.J Clin Oncol,10: 474–482, 1992.
20.
HinkleG.H., LoeschJ., NinesR., DePalatisL., HouchensD.P.: Radioiodination, quality assessment, in vitro and in vivo stability of iodine-125 Nofetumomab.J Labelled Cpd Radio-pharm, XLI: 423–434, 1998.
21.
BurakW.E., DePalatisL., NinesR., HitchcockC., HinkleG., HouchensD., FarrarW.B.: Biodistribution and localization of radiolabeled NR-LU-10 Fab fragment in human breast cancer xenografts.J Nucl Med Biol,25: 633–637, 1998.
22.
FisherB., AndersonS.: Conservative surgery for the management of invasive and noninvasive carcinoma of the breast.World J Surg,18: 63–69, 1994.
23.
FowbleB., SolinL.J., SchultzD.J., GoodmanR.L.: Ten year results of conservative surgery and irradiation for stage I and II breast cancer.Int J Radiat Oncol Biol Phys,21: 269–277, 1991.
24.
KurtzJ.M., AmalricR., BrandoneH., AymeY., JacquemierJ., PietraJ.C., HansD., PollettJ.F., BressacC., SpitalierJ.M.: Local recurrence after breast conserving surgery and radiotherapy.Cancer,63: 1912–1917, 1989.
25.
WeberS., StormF.K., StittJ., MahviD.M.: The role of frozen section analysis of margins during breast conservation surgery.Cancer J,3: 273–277, 1997.
26.
CoxC., KuN., ReintgenD., GreenburgH.M., NicosiaS.V., Wan-gensteenS.: Touch preparation cytology of breast lumpectomy margins with histologic correlation.Arch Surg,125: 490–493, 1991.
27.
BaumR.P., BrummendorfT.H.: Radioimmunolocalization of primary and metastatic breast cancer.Q J Nucl Med,42: 33–42, 1998.
28.
RijksL.J., BakkerP.J., van TienhovenG., NoorduynL.A., BoerG.J., RietbroikR.C., TaatC.W., JanssenA.G., VeenhofC.H., Van RoyenE.A.: Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE.J Clin Oncol,15: 2536–2545, 1997.
29.
WahlR.L.: Overview of the current status of PET in breast cancer imaging.Q J Nucl Med,42: 1–7, 1998.
